HGH Frag 176-191: What the Evidence Actually Shows About This Lipolytic Peptide

What Is HGH Fragment 176-191?

HGH Fragment 176-191 is the C-terminal segment of the 191-amino-acid human growth hormone molecule, spanning positions 176 through 191. Researchers at Monash University isolated this region in the 1990s after observing that the full GH molecule's fat-burning activity resided in this short tail rather than in the receptor-binding domain responsible for growth and insulin resistance. The isolated fragment retains the ability to stimulate lipolysis and inhibit lipogenesis while producing no measurable change in blood glucose or serum IGF-1 at doses tested in animals and early human trials [1].

In rodent models, AOD 9604 reduced body fat by roughly 50% more than saline controls over a 7-day infusion period without altering fasting glucose, a finding published by Heffernan and colleagues [2]. That dissociation between metabolic activity and growth-promoting activity is the pharmacological argument the compound's developers used to advance it toward human trials. The compound activates beta-3 adrenergic receptors on adipocytes, a pathway that also responds to catecholamines during aerobic exercise [3].

No anabolic signaling through the GH receptor's JAK2-STAT5 pathway has been detected for this fragment, which is why researchers expected it to carry a lower side-effect burden than recombinant hGH. That expectation held in Phase I and II trials, though the program never advanced to Phase III [4].

How AOD 9604 Differs From Full-Length Growth Hormone

Full recombinant human growth hormone (somatropin) stimulates the GH receptor throughout the body, raising IGF-1, promoting linear bone growth, increasing lean mass, and causing insulin resistance at supraphysiological doses [5]. The FDA has approved somatropin (Genotropin, Norditropin, Humatrope, among others) for a narrow set of indications including adult GH deficiency, Turner syndrome, Prader-Willi syndrome, and short bowel syndrome [6].

AOD 9604 skips all of that. The fragment does not bind the classical GH receptor in the way full-length hGH does. A 2001 paper by Heffernan et al. in Endocrinology confirmed that AOD 9604 failed to stimulate IGF-1 production in hypophysectomized rats even at doses 400-fold higher than those producing measurable lipolysis [2]. That mechanistic separation explains why the compound attracted pharmaceutical investment as an anti-obesity candidate rather than a performance-enhancing drug.

Somatropin at therapeutic doses for GH-deficient adults (0.15 to 0.30 mg/day subcutaneous) raises IGF-1 into the normal adult range and costs roughly $800 to $3,000 per month depending on brand and dose [6]. AOD 9604 at the doses used in Phase IIb (1 mg oral) did not raise IGF-1 at all, which removes one of the most closely monitored safety signals in GH therapy [4].

The IGF-1 distinction also has regulatory implications. Misuse of somatropin for performance enhancement is a Schedule III offense under the Human Growth Hormone Act of 1990 [7]. AOD 9604 does not appear on the Controlled Substances Act schedule, though the FDA has not approved it and the World Anti-Doping Agency (WADA) prohibits it under the S2 peptide hormones category [8].

Human Trial Data: What Phase II Actually Showed

Metabolic Pharmaceuticals Ltd. ran a Phase IIb randomized, double-blind, placebo-controlled trial in 300 obese adults (mean BMI 34 kg/m²) over 12 weeks, testing oral AOD 9604 at doses ranging from 0.25 mg to 1 mg daily. The trial measured body weight, total fat mass by DEXA, fasting glucose, fasting insulin, and lipid panels [4].

At the highest dose (1 mg/day), subjects lost a mean of 2.1 kg more fat mass than placebo over 12 weeks. Fasting glucose and insulin did not change significantly from baseline in any active-dose arm (P<0.05 threshold not met for metabolic endpoints). The compound was well tolerated with no serious adverse events attributed to the drug [4].

That weight-loss figure sounds modest. For context, the GLP-1 receptor agonist semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body-weight loss (approximately 15.3 kg) at 68 weeks in the STEP-1 trial (N=1,961) [9]. AOD 9604's 2.1 kg additional fat loss over 12 weeks at 1 mg/day is substantially smaller, and the trial ended before a Phase III program was initiated. Metabolic Pharmaceuticals halted development; the compound has not re-entered a registered Phase III trial as of the 2025 ClinicalTrials.gov database.

A separate pilot study (N=24) examined subcutaneous AOD 9604 at 250 mcg twice daily over 8 weeks and found no statistically significant change in body composition versus placebo, though the study was underpowered [10]. The oral route produced better results in Phase IIb, which the investigators attributed to enterohepatic circulation concentrating the peptide in fat-adjacent portal tissue.

HealthRX Clinical Interpretation Framework: AOD 9604 Evidence Tier

| Evidence Domain | Finding | Confidence | |---|---|---| | Lipolysis (animal) | Confirmed, dose-dependent | High (multiple replications) | | IGF-1 neutrality (animal) | Confirmed up to 400x lipolytic dose | High | | Fat loss (human, Phase IIb) | 2.1 kg vs placebo at 12 weeks, 1 mg oral | Moderate (single completed trial) | | Glycemic safety (human) | No significant change | Moderate | | Long-term safety (>12 weeks) | No data | None | | Approved clinical use | Not approved anywhere | N/A |

Dosing Protocols in Research and Gray-Market Use

The only dose ranges with any human safety data are those from Metabolic Pharmaceuticals' Phase II program: 0.25 mg, 0.5 mg, and 1 mg orally per day for 12 weeks [4]. Subcutaneous formulations circulating on research-chemical markets are typically sold at 2 mg/vial, with users self-administering 250 mcg to 500 mcg subcutaneously once or twice daily, often peri-workout. No peer-reviewed trial has validated subcutaneous dosing for body composition in humans.

The FDA explicitly states that peptides sold as "research chemicals" for human self-administration fall outside the investigational new drug (IND) exemption and are subject to enforcement [11]. Purchasing AOD 9604 for personal injection therefore carries both legal and safety risks that no published trial has characterized at those specific routes and doses.

Melanotan I: What It Is and Why the FDA Flagged It

Melanotan I (afamelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that binds melanocortin-1 receptors (MC1R) on melanocytes, increasing eumelanin production and darkening skin before UV exposure [12]. It was developed as a photoprotective agent for patients with erythropoietic protoporphyria (EPP), a painful inherited disorder triggered by light exposure.

The European Medicines Agency approved afamelanotide (Scenesse, 16 mg subcutaneous implant every 60 days) for EPP in adults in 2014. The FDA approved the same product in October 2019, making it the first MC1R agonist with regulatory approval anywhere in the world [13]. Outside that single indication, any use of afamelanotide or compounded "Melanotan I" is off-label or illegal depending on formulation source.

The FDA issued Import Alert 66-71 covering unapproved synthetic melanotropin peptides including Melanotan I and Melanotan II, directing field offices to detain shipments without physical examination [14]. Compounded or gray-market Melanotan I carries no guaranteed purity standard and has not been tested for long-term melanoma risk in large human cohorts, though the MC1R pathway is known to interact with UV-induced mutagenesis in melanocytes [15].

Melanotan II: A Different Peptide With a Different Risk Profile

Melanotan II (MT-II) is not the same molecule as Melanotan I. It is a cyclic heptapeptide that binds MC1R, MC3R, MC4R, and MC5R. The broader receptor activation profile produces effects far beyond skin darkening: spontaneous erections (via MC4R in the hypothalamus), appetite suppression, and sexual arousal [16].

The sexual side-effect profile generated early clinical interest. PT-141 (bremelanotide), a closely related compound, was eventually approved by the FDA in June 2019 as Vyleesi (1.75 mg subcutaneous) for hypoactive sexual desire disorder in premenopausal women [17]. That approval required a full Phase III program and a REMS program because of transient blood pressure increases seen during trials.

Melanotan II itself has never received approval anywhere. Case reports and pharmacovigilance data document serious adverse events including:

• Priapism requiring emergency intervention [18]
• Hypertensive crises in individuals with pre-existing cardiovascular risk [19]
• Nausea and vomiting at doses above 0.5 mg [16]
• Mole darkening and new nevi formation, raising dermatology concerns [20]

A 2009 case series published in the Journal of Clinical Endocrinology and Metabolism described three men who developed rapid darkening of existing melanocytic nevi after self-administering compounded MT-II, with one lesion requiring excision and histologic review [20]. The authors recommended dermatologic screening before and during any MC receptor agonist use.

The cardiovascular risk is the most clinically pressing concern. Because MT-II acts on MC3R and MC4R in the hypothalamus, it can raise mean arterial pressure acutely. The Phase III trial for bremelanotide (the approved analogue) showed a mean peak systolic blood pressure increase of 6 mmHg and a mean peak diastolic increase of 4 mmHg within two hours of dosing [17]. In a person with stage 1 hypertension already, that increment could be clinically significant.

Purchasing MT-II from research-chemical suppliers provides no quality assurance. A 2013 analysis of gray-market peptide vials purchased online found that 57% of samples contained less active compound than labeled, and 23% showed bacterial endotoxin contamination above the USP limit [21].

Myostatin Inhibitors: The Science and the Current Dead Ends

Myostatin (GDF-8) is a member of the TGF-beta superfamily produced primarily in skeletal muscle. It limits muscle fiber growth through the Smad2/3 signaling pathway. Animals with natural myostatin loss-of-function mutations, including the Belgian Blue cattle breed and documented human cases, develop extraordinary skeletal muscle mass without apparent cognitive or cardiovascular penalties [22].

That biology has made myostatin inhibition one of the most pursued targets in muscle-wasting disease research. The clinical candidates have included:

ACE-031 (a soluble activin receptor IIB fusion protein from Acceleron Pharma). Phase II trials in Duchenne muscular dystrophy (DMD) were halted in 2013 after participants developed epistaxis, gingival bleeding, and telangiectasias, adverse effects attributed to off-target inhibition of other TGF-beta ligands through the shared activin receptor [23].

Landogrozumab (LY2495655, Eli Lilly). A monoclonal antibody against myostatin tested in elderly sarcopenic adults (Phase II, N=222). At 315 mg subcutaneous every 4 weeks for 24 weeks, lean mass increased by 1.5 kg versus placebo, but functional outcomes (6-minute walk, stair climb power) did not improve significantly [24]. The program did not advance.

Apitegromab (Scholar Rock). A selective myostatin inhibitor tested in spinal muscular atrophy (SMA). The Phase III SAPPHIRE trial (N=130) in ambulatory SMA patients on nusinersen or risdiplam showed a statistically significant improvement in motor function at 12 months compared to placebo [25]. FDA accepted the Biologics License Application; a decision is expected in 2025.

Follistatin gene therapy (AAV-mediated overexpression). Ongoing trials at Nationwide Children's Hospital (NCT02354781) in Becker muscular dystrophy showed increased muscle volume on MRI but mixed functional results at 5-year follow-up [26].

No myostatin inhibitor has been approved for healthy adults seeking muscle gain. Every approved or near-approved candidate targets a specific disease population. Off-label use of research-chemical "myostatin inhibitors" sold online carries uncharacterized safety risks given the ACE-031 bleeding signal and the broad TGF-beta biology involved.

The FDA has issued warning letters to several supplement companies marketing products as "myostatin inhibitors" after finding no evidence that oral compounds cross the gastrointestinal barrier intact at concentrations sufficient to inhibit myostatin activity in muscle tissue [27].

Comparing These Peptides: Clinical Context for Each

These four compound categories (HGH frag 176-191, melanotan I, melanotan II, myostatin inhibitors) are often grouped together under the "specialty peptides" umbrella on bodybuilding forums, but their mechanisms, risk profiles, and evidence bases differ substantially.

HGH Fragment 176-191 has the most coherent human safety dataset of the group, limited though it is. The Phase IIb trial demonstrated a clean metabolic profile at oral doses up to 1 mg/day for 12 weeks [4]. Melanotan I has one FDA-approved product for one rare disease; everything else sold under that name is unregulated [13]. Melanotan II carries documented cardiovascular and dermatologic risks with no approved human indication [17, 18, 19, 20]. Myostatin inhibitors remain disease-specific investigational biologics, with bleeding and vascular adverse events ending the broadest clinical program in 2013 [23].

A clinician advising a patient asking about any of these compounds should distinguish between the compound's theoretical mechanism and the actual evidence base. The GLP-1 receptor agonist class (semaglutide, tirzepatide) has the largest and most methodologically rigorous weight-loss dataset available, with STEP-1 showing 14.9% weight loss at 68 weeks [9] and SURMOUNT-1 (N=2,539) showing 20.9% weight loss with tirzepatide 15 mg at 72 weeks [28]. Any fat-loss peptide candidate must be evaluated against that comparator when counseling patients.

Safety Signals and Monitoring Considerations

For patients who disclose self-use of HGH Fragment 176-191 or AOD 9604, the HealthRX medical team recommends baseline and periodic monitoring of fasting glucose, fasting insulin, IGF-1, and a basic metabolic panel, even though published trials showed no glycemic perturbation. The 12-week trial duration cannot exclude longer-term effects [4].

For patients disclosing MT-II use, a baseline blood pressure measurement, a full skin examination by a dermatologist, and a cardiovascular risk assessment using the ACC/AHA pooled cohort equations are warranted [29]. Patients with hypertension, a personal or family history of melanoma, or documented cardiovascular disease should be counseled to stop immediately.

Injection-site hygiene guidance applies across all subcutaneous peptides. The 23% endotoxin contamination rate found in gray-market vials [21] creates real risk of injection-site abscess and systemic bacteremia.

Legal and Regulatory Status Summary

The FDA has not approved HGH Fragment 176-191, Melanotan II, or any myostatin inhibitor for general human use. Melanotan I (afamelanotide/Scenesse) is approved only for EPP [13]. WADA prohibits all four categories in competitive athletes under the S2 (Peptide Hormones, Growth Factors, Related Substances) and S4 (Hormone and Metabolic Modulators) sections of the 2024 Prohibited List [8].

The FDA's guidance on compounded peptide drugs, updated in March 2024, explicitly removed several peptides including AOD 9604 from the list of bulk drug substances that may be used in compounding under Section 503A and 503B, meaning licensed compounding pharmacies in the United States may no longer legally prepare them for human administration [30].